Epigenomics AG / Key word(s): Change in ForecastEpigenomics AG: Further raise of earnings guidance for the current fiscal year 2022 21-Dec-2022 / 11:18 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for […]
Category: Insider Information
21. December 2022
Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022
Read more
14. December 2022
Epigenomics Releases Performance Data on Next Generation Test
Epigenomics AG / Key word(s): Study results/MiscellaneousEpigenomics Releases Performance Data on Next Generation Test 14-Dec-2022 / 05:11 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Epigenomics […]
19. September 2022
Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
Epigenomics AG / Key word(s): Change in Forecast/ForecastEpigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs 19-Sep-2022 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS – a service of EQS Group […]
09. September 2022
Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
Epigenomics AG / Key word(s): Corporate Action/AGM/EGM Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 09-Sep-2022 / 19:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content […]
20. August 2021
Epigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share
Epigenomics AG / Key word(s): Issue of Debt/Corporate ActionEpigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share 20-Aug-2021 / 10:41 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by […]
17. August 2021
Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance
Epigenomics AG / Key word(s): Strategic Company Decision/Change in ForecastEpigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance 17-Aug-2021 / 21:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for […]